Long Noncoding RNA Functions As a Competing Endogenous RNA to Promote Metastasis and Oxaliplatin Resistance by Sponging MiR-136 in Colorectal Cancer

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2017 Jan 25

PMID 28115855

Citations 47

Authors

Hongyan Gao

Xiaodi Song

Ting Kang

Baohong Yan

Li Feng

Li Gao

Liang Ai

Xiaoni Liu

Jie Yu

Huiqi Li

Affiliations

Soon will be listed here.

Abstract

Colorectal neoplasia differentially expressed () is a novel gene recognized as a long noncoding RNA (lncRNA) that is highly elevated in colorectal cancer and many other solid tumors but its functions on metastasis and oxaliplatin (OXA) resistance are unknown. In our study, we confirmed the upregulation of in both primary specimens from colorectal cancer patients and colorectal cancer cell lines. Knockdown of expression inhibited the migration and invasion potency of colorectal cancer cells with no effect on cell apoptosis. Overexpression of promoted the migration and invasion potency of colorectal cancer cells. Furthermore, we found that conferred chemoresistance in colorectal cancer cells. Knockdown of with OXA treatment decreased cell viability and promoted DNA damage and cell apoptosis, while the overexpression of with OXA treatment reduced DNA damage and cell apoptosis. Further in-depth mechanistic studies revealed that functioned as a competing endogenous RNA for miR-136, led to the de-repression of its endogenous target, E2F transcription factor 1 (E2F1). Overall, our findings demonstrate that functions as a competing endogenous RNA to promote metastasis and OXA resistance by sponging miR-136 in colorectal cancer.

Citing Articles

Identification of key lncRNAs associated with oxaliplatin resistance in colorectal cancer cells and isolated exosomes: From In-Silico prediction to In-Vitro validation.

Sahebnasagh R, Deli H, Shadboorestan A, Vakili-Ghartavol Z, Salehi N, Komeili-Movahhed T PLoS One. 2024; 19(10):e0311680.

PMID: 39401197 PMC: 11472961. DOI: 10.1371/journal.pone.0311680.

Navigating the labyrinth of long non-coding RNAs in colorectal cancer: From chemoresistance to autophagy.

Yu J, Sun C, Xu H, Jiang Y, Jiang X, Ni S World J Gastrointest Oncol. 2024; 16(8):3376-3381.

PMID: 39171173 PMC: 11334040. DOI: 10.4251/wjgo.v16.i8.3376.

Current concepts of the crosstalk between lncRNA and E2F1: shedding light on the cancer therapy.

Huang P, Wen F, Li Q Front Pharmacol. 2024; 15:1432490.

PMID: 39119602 PMC: 11306149. DOI: 10.3389/fphar.2024.1432490.

CRNDE: A Pivotal Oncogenic Long Non-Coding RNA in Cancers.

Hor Y, Salvamani S, Gunasekaran B, Yian K Yale J Biol Med. 2024; 96(4):511-526.

PMID: 38161583 PMC: 10751873. DOI: 10.59249/VHYE2306.

Exosomal non-coding RNAs: Blueprint in colorectal cancer metastasis and therapeutic targets.

Hussen B, Abdullah S, Abdullah S, Younis Y, Hidayat H, Rasul M Noncoding RNA Res. 2023; 8(4):615-632.

PMID: 37767111 PMC: 10520679. DOI: 10.1016/j.ncrna.2023.09.001.

References

Ma Y, Xin Y, Li R, Wang Z, Yue Q, Xiao F . TFDP3 was expressed in coordination with E2F1 to inhibit E2F1-mediated apoptosis in prostate cancer. Gene. 2014; 537(2):253-9. DOI: 10.1016/j.gene.2013.12.051. View

Engelmann D, Putzer B . The dark side of E2F1: in transit beyond apoptosis. Cancer Res. 2012; 72(3):571-5. DOI: 10.1158/0008-5472.CAN-11-2575. View

Knoll S, Emmrich S, Putzer B . The E2F1-miRNA cancer progression network. Adv Exp Med Biol. 2013; 774:135-47. DOI: 10.1007/978-94-007-5590-1_8. View

Concha-Benavente F, Srivastava R, Trivedi S, Lei Y, Chandran U, Seethala R . Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFNγ That Induce PD-L1 Expression in Head and Neck Cancer. Cancer Res. 2015; 76(5):1031-43. PMC: 4775348. DOI: 10.1158/0008-5472.CAN-15-2001. View

Velez-Cruz R, Johnson D . E2F1 and p53 transcription factors as accessory factors for nucleotide excision repair. Int J Mol Sci. 2012; 13(10):13554-68. PMC: 3497341. DOI: 10.3390/ijms131013554. View

Kelland L . The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007; 7(8):573-84. DOI: 10.1038/nrc2167. View

Qian X, Yu J, Yin Y, He J, Wang L, Li Q . MicroRNA-143 inhibits tumor growth and angiogenesis and sensitizes chemosensitivity to oxaliplatin in colorectal cancers. Cell Cycle. 2013; 12(9):1385-94. PMC: 3674066. DOI: 10.4161/cc.24477. View

Crosby M, Almasan A . Opposing roles of E2Fs in cell proliferation and death. Cancer Biol Ther. 2005; 3(12):1208-11. PMC: 2519115. DOI: 10.4161/cbt.3.12.1494. View

Chen J, Huang X, Qiao L, Katsifis A . Insulin caused drug resistance to oxaliplatin in colon cancer cell line HT29. J Gastrointest Oncol. 2012; 2(1):27-33. PMC: 3397588. DOI: 10.3978/j.issn.2078-6891.2010.028. View

10.

Poppy Roworth A, Ghari F, La Thangue N . To live or let die - complexity within the E2F1 pathway. Mol Cell Oncol. 2016; 2(1):e970480. PMC: 4905241. DOI: 10.4161/23723548.2014.970480. View

11.

Zheng J, Liu X, Wang P, Xue Y, Ma J, Qu C . CRNDE Promotes Malignant Progression of Glioma by Attenuating miR-384/PIWIL4/STAT3 Axis. Mol Ther. 2016; 24(7):1199-1215. PMC: 5088760. DOI: 10.1038/mt.2016.71. View

12.

Li Z, Hou M, Wang H, Wang Z . [A randomized study of gemcitabine plus oxaliplatin versus gemcitabine plus cisplatin as the 1st line chemotherapy for advanced non-small cell lung cancer in elderly patients]. Zhongguo Fei Ai Za Zhi. 2011; 14(7):588-92. PMC: 6000267. DOI: 10.3779/j.issn.1009-3419.2011.07.05. View

13.

Yu H, Lee H, Herrmann A, Buettner R, Jove R . Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer. 2014; 14(11):736-46. DOI: 10.1038/nrc3818. View

14.

Laine A, Westermarck J . Molecular pathways: harnessing E2F1 regulation for prosenescence therapy in p53-defective cancer cells. Clin Cancer Res. 2014; 20(14):3644-50. DOI: 10.1158/1078-0432.CCR-13-1942. View

15.

Chang W, Andrews J, Carter D, Dagnino L . Differentiation and injury-repair signals modulate the interaction of E2F and pRB proteins with novel target genes in keratinocytes. Cell Cycle. 2006; 5(16):1872-9. DOI: 10.4161/cc.5.16.3136. View

16.

Redmond K, Papafili A, Lawler M, Van Schaeybroeck S . Overcoming Resistance to Targeted Therapies in Cancer. Semin Oncol. 2015; 42(6):896-908. DOI: 10.1053/j.seminoncol.2015.09.028. View

17.

Ekblad L, Johnsson A . Cetuximab sensitivity associated with oxaliplatin resistance in colorectal cancer. Anticancer Res. 2012; 32(3):783-6. View

18.

Wu H, Liu Q, Cai T, Chen Y, Liao F, Wang Z . MiR-136 modulates glioma cell sensitivity to temozolomide by targeting astrocyte elevated gene-1. Diagn Pathol. 2014; 9:173. PMC: 4195982. DOI: 10.1186/s13000-014-0173-0. View

19.

Chen J, Zhang X, Proud C . Dissecting the signaling pathways that mediate cancer in PTEN and LKB1 double-knockout mice. Sci Signal. 2015; 8(392):pe1. DOI: 10.1126/scisignal.aac8321. View

20.

Cataldo A, Cheung D, Balsari A, Tagliabue E, Coppola V, Iorio M . miR-302b enhances breast cancer cell sensitivity to cisplatin by regulating E2F1 and the cellular DNA damage response. Oncotarget. 2015; 7(1):786-97. PMC: 4808033. DOI: 10.18632/oncotarget.6381. View